INTRODUCTION

Polymorphic light eruption (PLE) is the most common photodermatosis and is especially prevalent among young women in temperate climates. Severely affected individuals, who experience repeated attacks of PLE throughout the summer, may require prophylactic medical photohardening each spring before the first intense sun exposure. Medical photohardening simulates the naturally occurring phenomenon of hardening and aims to induce photoadaption. Broadband UVB (290-320 nm) (BB-UVB), narrowband UVB (311-313 nm) (NB-UVB), and psoralen plus UVA (PUVA) photochemotherapy are effective in photohardening of PLE. Although it is well known that medical phototherapy can lead to PLE, little is known about the frequency of such events. The aim of this study was to investigate the frequency of PLE under prophylactic photohardening in PLE-prone patients. Additionally, we investigated the frequency of occurrence of PLE in patients treated with photohardening and patients treated with phototherapy for other diseases.
frequency of PLE during phototherapy in patients with other diseases, including psoriasis, atopic eczema, prurigo, parapsoriasis en plaques and mycosis fungoides, pityriasis lichenoides chronica (PLC) or pityriasis lichenoides eruptiva et varioliformis acuta (PLEVA), granuloma anulare, and scleroderma.

## 2 | MATERIALS AND METHODS

### 2.1 | Study design

This was a retrospective case study of the occurrence of PLE over a 4-year period (from January 2013 to December 2016) in patients treated with phototherapy at the Photodermatology Unit, Department of Dermatology, Medical University of Graz, Austria. The data for analysis were obtained from the electronic health and patient record database and patient files of the Photodermatology Unit. The study was approved by the Ethics Committee of the Medical University of Graz through protocol number 25-294 ex 12/13.

### 2.2 | Patient identification

First, we electronically searched the database to identify patients (irrespective of primary diagnosis) who underwent phototherapy and exhibited PLE under treatment. Key search terms were “polymorphous,” “polymorphic,” “PLE,” and “PLD” (ie, the German abbreviation of PLE) in the data fields of “diagnosis,” “patient history,” and “course of disease” in the database. The patient records so identified were then screened for prior history from 1998 onward. Second, we electronically searched the database for records of all patients with the specific diagnoses listed in Table 1 in whom PLE had occurred and who had been identified in the first step of our electronic database search. The key words for the diagnoses were the primary designation of a specific diagnosis (eg, psoriasis); in addition, for each diagnosis, we used related abbreviations and characteristic, truncated parts of diagnostic terms (such as “psor” and others) to identify and include the data of patients whose diagnoses may have been potentially misspelled in the database. Then, we performed automatic and manual data extractions to obtain patient demographics, history, and phototherapy characteristics.

### 2.3 | Statistical analysis

Descriptive data from our analyses were presented in tables. The Fisher exact or chi-square test, as appropriate, was used to compare the prevalence of PLE under phototherapy between different groups of patients. A P value $P < 0.05$ was considered significant.

## 3 | RESULTS

Our electronic database search identified the occurrence of PLE under photohardening (in any cycle) in 24.3% (18/74) of PLE patients (Table 1). Photohardening with suberythemal dosages of NB-UVB had been administered to all PLE patients during phototherapy treatment cycles 2-3 times per week for 4-6 weeks in spring, at a starting dose of 0.2 J/cm² and in dose increments of 0.05–0.1 J/cm² per treatment, as tolerated. The other forms of phototherapy had been administered to the PLE patients, as previously described.

The frequency of PLE in patients with other diseases treated with minimal phototoxic dose- or skin phototype-based suberythemal phototherapy ranged from 0.4% (psoriasis) to 16.7% (PLEVA). PLE occurred significantly more often in PLE-prone patients who underwent photohardening than in psoriasis patients who underwent phototherapy ($P < 0.0001$). Compared with its occurrence in patients with psoriasis (the disease with the lowest observed prevalence of PLE), PLE occurred significantly more often under phototherapy in patients with parapsoriasis en plaques/mycosis fungoides (3.5%, $P = 0.0206$), granuloma anulare (7.4%, $P = 0.0013$), scleroderma (14.3%, $P = 0.0002$), and PLEVA (16.7%, $P < 0.0001$) (Table 1). The frequency of PLE in patients with atopic eczema and prurigo was low and did not differ statistically from that in patients with psoriasis. PLE occurrence did not appear to be affected by wavebands or phototherapeutic modalities administered to the patients (Table 1). The demographics and phototherapy characteristics of PLE patients undergoing phototherapy are presented for individual patients in Table 2 and then summarized in Table 3. Under daily life conditions and exposure to natural sunlight, more women than men experienced PLE under photohardening (ie, 16 vs 2) (Table 1), consistent with the observation that more women than men overall had undergone photohardening. Surprisingly, however, the female/male ratio in non-PLE patients (7/9) was more balanced, despite a similar overall number of phototherapy-treated women and men in non-PLE patient groups. Besides, there were no major differences in phototherapy characteristics between PLE patients and non-PLE patients. For instance, in PLE patients, the disease manifested after a median of five treatment exposures in the first cycle of occurrence, compared with 5.5 treatment exposures in non-PLE patients (Table 3). In general, the occurrence of PLE in a patient did not result in a change of the allocated standard treatment protocol, though some of them received short-term topical steroids to mitigate the rash.

## 4 | DISCUSSION

In this Austrian study, PLE occurred in 24% (18/74) of PLE patients under photohardening, a percentage considerably lower than the 56% (44/79) recently reported in a 5-year single-center, case-series review from Scotland. The reasons for this difference remain elusive, but may be partly due to differences in phototherapy treatment protocols and/or skin phototype. In our study, the minority (21%, 3/14) of phototyped PLE patients who exhibited disease symptoms under photohardening were of skin phototype I/II, compared with the majority (76%, 60/79) in the Scottish study.

Notably, our results showed a very low prevalence of PLE in psoriasis patients undergoing phototherapy (0.7%, [3/421]), even though...
**TABLE 1**  Frequency of PLE manifestation during phototherapy in patients with different diseases

| Primary diagnosis | Number of patients (females/males) with PLE at any phototherapy cycle/total number of patients (females/males) | Number of phototherapy cycles with occurrence of PLE/total number of phototherapy cycles |
|------------------|---------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------|
|                  |                                                                                                              | All wavebands | NB-UVB | BB-UVB | PUVA | UVA1 |
| PLE              | 18 (16/2)/74 (65/9) (24.3)                                                                                   | 26/130 (20.0) | 22/113 (19.5) | 4/13 (30.8), *P = 0.34 | 0/4 (0) | - |
|                  |                                                                                                              | *P < 0.0001  |        |        |      |      |
| Other diagnoses  |                                                                                                              |             |        |        |      |      |
| Atopic Eczema    | 3 (1/2)/257 (123/134) (1.2)                                                                                   | 3/339 (0.9)  | 1/212 (0.5) | 0/8 (0) | 1/36 (2.8) | 1/83 (1.2) |
|                  |                                                                                                              | *P = 0.54  |        |        |      |      |
| Erythroderma     | 1 (0/1)/23 (9/14) (4.3)                                                                                      | 1/29 (3.4)  | 1/7 (14.3) | -      | 0/20 (0) | 0/2 (0) |
|                  |                                                                                                              | *P = 0.07  |        |        |      |      |
| Granuloma anulare| 2 (1/1)/27 (21/6) (7.4)                                                                                      | 3/35 (8.6)  | 0/2 (0)  | -      | 2/24 (8.3) | 1/9 (11.1) |
|                  |                                                                                                              | *P = 0.001 |        |        |      |      |
| Parapsoriasis en plaques, Mycosis fungoides | 4 (2/2)/115 (24/91) (3.5)                                                                                   | 4/180 (2.2) | 2/82 (2.4) | -      | 2/98 (2.0) | - |
|                  |                                                                                                              | *P = 0.02  |        |        |      |      |
| PLEVA/PLC        | 1 (0/1)/6 (2/4) (16.7)                                                                                       | 1/6 (16.7)  | 0/2 (0)  | -      | 1/4 (25.0) | - |
|                  |                                                                                                              | *P < 0.0001 |        |        |      |      |
| Prurigo          | 1 (0/1)/118 (73/45) (0.8)                                                                                    | 1/162 (0.6) | 0/117 (0) | 0/18 (0) | 1/12 (8.3) | 0/15 (0) |
|                  |                                                                                                              | *P = 0.88  |        |        |      |      |
| Psoriasis        | 3 (2/1)/421 (181/240) (0.7)                                                                                   | 3/686 (0.4) | 3/552 (0.5) | 0/1 (0) | 0/133 (0) | - |
|                  |                                                                                                              | n.a.        |        |        |      |      |
| Scleroderma      | 1 (1/0)/7 (5/2) (14.3)                                                                                        | 1/11 (9.1)  | -      | -      | 0/1 (0) | 1/10 (10.0) |
|                  |                                                                                                              | *P = 0.0002 |        |        |      |      |
| Total of other diagnoses | 16 (7/9)/974 (438/536)                                                                                       | 17/1448 (1.2%) | 7/974 (0.7%) | 0/27 (0.0%), *P = 0.658 | 7/328 (2.1%) | 3/119 (2.5%) |

Frequency given as percentage in parentheses.

*P value was determined by Fisher exact or chi-square test, comparing the frequency of PLE manifestation in a certain disease vs that in psoriasis.

*P value was determined by Fisher exact test, comparing the frequency of PLE manifestation in NB-UVB vs BB-UVB cycles. –: none; n.a.: not available.
### TABLE 2  Demographics and phototherapy characteristics of individual PLE patients undergoing photohardening

| PLE patient no. | Gender | Skin phototype | Morphology of PLE lesions | Predilection body site | Disease duration at PLE onset during phototherapy, years | PLE occurrence at cycle number (exposure number)/total number of cycles per waveband |
|-----------------|--------|----------------|---------------------------|------------------------|----------------------------------------------------------|---------------------------------------------------------------------------------|
| 1               | f      | 3              | macpap                    | VN, N, FA, T           | 13                                                       | 1 (1)/1 NB-UBV                                                                 |
| 2               | f      | 3              | mac                       | VN, T, UA, FA          | 29                                                       | 1 (15), 1 (3)/7 NB-UVB                                                          |
| 3               | f      | 3              | urt                       | VN, UA, N, AB          | 6                                                        | 3 (10), 4 (7), 6 (2,7)/6 NB-UVB                                                 |
| 4               | f      | 1              | urt                       | VN, FA                 | 16                                                       | 1 (1)/1 NB-UVB                                                                 |
| 5               | f      | 2              | urt                       | VN, N, UA, FA          | 5                                                        | 2 (5)/3 NB-UVB                                                                 |
| 6               | f      | 3              | macpap                    | FAC, N, VN, UA, FA, L, H, F | 40                                                      | 1 (1)/1 BB-UVB, 0 (0)/3 NB-UVB                                                  |
| 7               | m      | 3              | pap                       | VN                     | 3                                                        | 1 (1,4,16), 2 (7,9)/2 NB-UVB                                                    |
| 8               | f      | 3              | pap                       | FAC, N, VN, AB, UA, FA, T | 5                                                        | 1 (3)/1 NB-UVB                                                                 |
| 9               | f      | 3              | papves                    | VN, UA, FA, T, L       | 14                                                       | 1 (2,6)/1 NB-UVB                                                               |
| 10              | m      | 3              | pap                       | FA, VN, B, T           | 2                                                        | 1 (11)/1 BB-UVB, 1 (5)/1 NB-UVB                                                |
| 11              | f      | na             | pap                       | VN, FA, UA             | 19                                                       | 1 (5,10,14)/1 BB-UVB                                                           |
| 12              | f      | na             | papves                    | VN, UA, FA, L, FAC, B  | 8                                                        | 1 (6)/1 NB-UVB                                                                 |
| 13              | f      | 2              | macpap                    | FA, VN, T              | 20                                                       | 1 (10), 1 (12), 4 (8)/4 NB-UVB                                                 |
| 14              | f      | 3              | papves                    | VN, UA, FA             | 16                                                       | 1 (14)/1 NB-UVB                                                                |
| 15              | f      | 3              | pap                       | VN                     | 6                                                        | 1 (9), 2 (9)/2 NB-UVB                                                           |
| 16              | f      | na             | pap                       | FAC, VN, UA, FA, AB    | 9                                                        | 1 (12)/1 BB-UVB                                                                |
| 17              | f      | na             | pap                       | VN                     | 19                                                       | 1 (2)/1 NB-UVB                                                                 |
| 18              | f      | 3              | mac                       | VN, T                  | 8                                                        | 1 (2,11)/1 NB-UVB                                                              |

VN: V-neck; N: neck; FA: forearm; UA: upper arm; T: thigh; AB: abdomen; FAC: face; L: lower leg; H: dorsal hands; F: dorsal feet; B: back; mac: macular; pap: papular; ves: vesicular; urt: urticarial.
TABLE 3  Summary of demographics and treatment characteristics of patients with PLE eruption occurring under phototherapy

| Primary diagnosis | Patient number | Gender | Median age (range), years | Skin phototype | Morphology of PLE lesions | Predilection body site | Median (range of) disease duration at PLE onset during phototherapy, years | Median exposure number (range of) with PLE occurrence in first cycle with PLE eruption | Number of patients with one or more positive cycles | First PLE eruption at phototherapy cycle number | Number of PLE positive cycles per total number of cycles |
|-------------------|----------------|--------|---------------------------|----------------|---------------------------|------------------------|-----------------------------------------------------------------|----------------------------------------------------------------|---------------------------------|---------------------------------|-------------------------------------------------|
| Non-PLE           | 16             | f:7    | m:9                       | lt: 1          | na: 1                     | pap:9 macpap:6 papves:1| VN: 10 B: 6 AB: 2 GLUT: 3 T: 3 UA: 2 L: 1 n.a.                     | One positive cycle, n = 16 | First cycle: 13/16 patients, second cycle: 3/6 patients* | n = 16/27, NB-UVB: 7/11 BB-UVB: 1/2 PUVA: 5/11 UVA1: 3/3 |
| PLE               | 18             | f:16   | m:2                       | lt: 2          | Ill: 11 na: 4             | mac:2 macpap:3 urt:3 papves:3 pap:7 | VN: 18 N: 5 FA:13 T: 7 UA: 10 AB: 3 FAC: 4 L: 3 H: 1 F: 1 B: 2 | 10.7, (2-40) | One positive cycle, n = 12, two positive cycles, n = 4 three positive cycles, n = 2 | n = 26/43, NB-UVB: 22/36 BB-UVB: 4/4 PUVA: 0/3 |

VN, V-neck; N, neck; FA, forearm; UA, upper arm; T, thigh; AB, abdomen; FAC, face; L, lower leg; H, dorsal hands; F, dorsal feet; B, back, GLUT, gluteal mac, macular; pap, papular; ves, vesicular; urt, urticular; *6 of the 16 patients had two or more (up to five) phototherapy cycles.

*Three of the 18 patients had two or more (up to three) phototherapy cycles.
PLE in psoriasis might not be so rare in the general population.\(^9\) PLE seems to be highly linked to photosensitive variants of psoriatic disease. In an epidemiologic study, 43\% of all patients suffering from photosensitive psoriasis were found to have a history of PLE with secondary exacerbation of psoriatic lesions.\(^10\) We recently speculated that resistance to UV-induced immune suppression in PLE may photoaggravate other diseases such as coexisting psoriasis, which commonly responds beneficially to UV radiation from sunlight or artificial sources.\(^9\) Psoriasis patients who are susceptible to PLE may not experience the beneficial antipsoriatic effects of UVB but may instead experience induction and/or worsening of psoriatic disease after UVB exposure. In these patients, UVB radiation may induce innate immunity through antimicrobial peptides such as cathelicidin LL-37, resulting in psoriatic lesions when there is simultaneous resistance to the UV-induced suppression of the adaptive immune response (like in PLE) that would normally counteract such lesions.\(^9\) Thus, patients with photosensitive psoriasis may not be allocated to UVB phototherapy (based on a history of photoaggravation that is possibly linked to PLE), which may in turn explain the very low prevalence of PLE in our series of psoriasis patients. In contrast, PUVA may act in photosensitive psoriasis without provoking PLE,\(^11,12\) consistent with our data showing that none of 133 psoriatic patients treated with PUVA developed PLE during treatment (Table 1).

However, we observed a relatively high frequency of PLE under phototherapy in patients with parapsoriasis en plaques/mycosis fungoides (3.5\%), granuloma anulare (7.4\%), scleroderma (14.3\%), and PLC/PLEVA (16.7\%). This may be due to differences in pathophysiology and immunological hyperresponsiveness to UV radiation between these conditions and non-photosensitive psoriasis. We observed PLE in a few non-PLE patients after UVA1 (340–400 nm) treatment, including one patient with scleroderma. PLE seems to be induced more often by UVA (320–400 nm) than by UVB (290–320 nm), but can also be induced by UVB alone and sometimes by both wavebands together (cited in\(^7\)). The role of UVA in triggering PLE has been well substantiated by phototest findings and the observation that most patients with PLE are sensitive to sunlight through window glass (cited in\(^7\)) and by the observed lack of protection from pure UVB-absorbing sunscreens.\(^13\)

Although the generalizability of our study’s findings is limited by the rather low patient numbers in some of the diseases examined and by the retrospective study design, our findings do suggest that PLE manifestation under photohardening occurs frequently in PLE-prone patients but variably in other diseases treated with phototherapy. This knowledge will be helpful for allocating treatment, estimating risk of PLE occurrence, and obtaining related informed consent not only from PLE-prone patients but also from patients with other skin disorders commonly treated with phototherapy.

ACKNOWLEDGEMENTS

The authors are very grateful to H.N. Ananthaswamy, Houston, Texas, for critical reading and Jude Richard, Austin, TX for editing of the manuscript.

CONFLICT OF INTEREST

None declared.

ORCID

Peter Wolf  http://orcid.org/0000-0001-7777-9444

REFERENCES

1. Rhodes LE, Bock M, Janssens AS, et al. Polymorphic light eruption occurs in 18\% of Europeans and does not show higher prevalence with increasing latitude: multicenter survey of 6,895 individuals residing from the Mediterranean to Scandinavia. J Invest Dermatol. 2010;130(2):626–628.
2. Gruber-Wackernagel A, Byrne SN, Wolf P. Polymorphous light eruption: clinic aspects and pathogenesis. Dermatol Clin. 2014;32(3):315–334.
3. Addo HA, Sharma SC. UVB phototherapy and photochemotherapy (PUVA) in the treatment of polymorphic light eruption and solar urticaria. Br J Dermatol. 1987;116(4):539–547.
4. Bilsland D, George SA, Gibbs NK, Aitchison T, Johnson BE, Ferguson J. A comparison of narrow band phototherapy (TL-01) and photochemotherapy (PUVA) in the management of polymorphic light eruption. Br J Dermatol. 1993;129(6):708–712.
5. Aslam A, Fullerton L, Ibbotson SH. Phototherapy and photochemotherapy for polymorphic light eruption desensitization: a five-year case series review from a university teaching hospital. Photodermatol Photoimmunol Photomed. 2017;33(4):225–227.
6. Man I, Dawe RS, Ferguson J. Artificial hardening for polymorphous light eruption: practical points from ten years’ experience. Photodermatol Photoimmunol Photomed. 1999;15(3–4):96–99.
7. Mastaler U, Kerl H, Wolf P. Clinical, laboratory, phototest and phototherapy findings in polymorphic light eruptions: a retrospective study of 133 patients. Eur J Dermatol. 1998;8(8):554–559.
8. Schweintzer N, Gruber-Wackernagel A, Reginato E, et al. Levels and function of regulatory T cells in patients with polymorphic light eruption: relation to photohardening. Br J Dermatol. 2015;173(2):519–526.
9. Wolf P, Weger W, Patra V, Gruber-Wackernagel A, Byrne SN. Desired response to phototherapy versus photo-aggravation in psoriasis: what makes the difference? Exp Dermatol. 2016;25:937–944.
10. Ros AM, Eklund G. Photosensitive psoriasis. An epidemiologic study. J Am Acad Dermatol. 1987;17:752–758.
11. Ros AM, Wennersten G. PUVA therapy for photosensitive psoriasis. Acta Derm Venereol. 1987;67(6):501–505.
12. Ros AM. Photosensitive psoriasis. Semin Dermatol. 1992;11(4):267–268.
13. Diffey BL, Farr PM. An evaluation of sunscreens in patients with broad action-spectrum photosensitivity. Br J Dermatol. 1985;112(1):83–86.

How to cite this article: Gruber-Wackernagel A, Hofer A, Legat F, Wolf P. Frequency of occurrence of polymorphic light eruption in patients treated with photohardening and patients treated with phototherapy for other diseases. Photodermatol Photoimmunol Photomed. 2019;35:100–105.
https://doi.org/10.1111/phpp.12429